Odonate Therapeutics Inc represents values of innovation, dedication, and patient-centric approach in the field of pharmaceuticals. The company is committed to developing and commercializing medicines to improve the lives of patients with cancer. Odonate Therapeutics fosters a corporate philosophy that emphasizes the importance of scientific research, clinical advancement, and collaboration with healthcare professionals. With a focus on oncology, the company strives to bring transformative therapies to patients in need. Odonate Therapeutics Inc seeks to revolutionize cancer treatment through groundbreaking advancements, ensuring hope and improved outcomes for individuals facing this devastating disease.

Odonate Therapeutics Inc is primarily present in the United States.

Odonate Therapeutics Inc has achieved significant milestones in its journey. The company successfully developed and gained approval for its lead product, tesetaxel, a chemotherapy drug. Tesetaxel has demonstrated promising results in clinical trials, showcasing its potential as an effective treatment for diverse forms of cancer. Odonate Therapeutics Inc also secured strategic collaborations with renowned institutions and organizations, further enhancing its research and development capabilities. These achievements position Odonate Therapeutics Inc as a key player in the biopharmaceutical industry, dedicated to improving patient outcomes and advancing cancer therapeutics.

Odonate Therapeutics Inc. is a biopharmaceutical company that focuses on the development and commercialization of innovative therapeutics for the treatment of cancer. The company was founded in 2013 and is headquartered in San Diego, California. Odonate's main product candidate, tesetaxel, is an oral chemotherapy drug currently in advanced clinical trials for the treatment of various types of cancer, including breast cancer. With a team of experienced professionals and a strong commitment to improving patient outcomes, Odonate Therapeutics Inc. is dedicated to bringing novel cancer therapies to market and making a positive impact in the field of oncology.

The main competitors of Odonate Therapeutics Inc in the market include pharmaceutical companies focused on developing and commercializing oncology treatments, such as Pfizer Inc, Merck & Co., Inc, and Novartis AG. These established players have a strong presence in the oncology market and offer a range of oncology therapeutics. However, Odonate Therapeutics Inc distinguishes itself by providing innovative therapies that specifically target and address unmet medical needs in the treatment of breast cancer.

Odonate Therapeutics Inc is primarily active in the healthcare industry.

The business model of Odonate Therapeutics Inc is focused on developing and commercializing innovative therapeutics for the treatment of cancer. The company is primarily engaged in the research, development, and clinical trials of its proprietary drug candidates, with a specific focus on the treatment of breast cancer. Odonate Therapeutics aims to address unmet medical needs and improve patient outcomes by delivering novel cancer treatments. By leveraging its expertise in oncology drug development, the company aims to create value for stakeholders and contribute to advancing the field of cancer therapeutics.

Το Ρ/Ε δεν μπορεί να υπολογιστεί αυτή τη στιγμή για το Odonate Therapeutics.

Το KUV δεν μπορεί να υπολογιστεί αυτή τη στιγμή για Odonate Therapeutics.

Το AlleAktien Qualitätsscore για το Odonate Therapeutics είναι 2/10.

Τα έσοδα δεν μπορούν να υπολογιστούν επί του παρόντος για Odonate Therapeutics.

Τα κέρδη για τον Odonate Therapeutics δεν μπορούν να υπολογιστούν αυτή τη στιγμή.

Odonate Therapeutics Inc is a biotechnology company that specializes in developing innovative therapies for cancer. The company focuses on developing drugs that can target and effectively fight cancer cells while being gentle on the patient's healthy tissue. The goal of Odonate Therapeutics is to improve the quality of life and prolong the survival time of cancer patients.

Η Odonate Therapeutics καταβάλλει μια διανομή της τάξεως των 0 USD διαμοιρασμένη σε δόσεις ετησίως.

Το μέρισμα δεν μπορεί να υπολογιστεί για το Odonate Therapeutics αυτή τη στιγμή ή η εταιρεία δεν διανέμει μέρισμα.

Ο αριθμός ISIN της Odonate Therapeutics είναι US6760791060.

Το WKN της Odonate Therapeutics είναι A2H9FC.

Ο τίκερ της Odonate Therapeutics είναι ODTC.

Κατά τους τελευταίους 12 μήνες η Odonate Therapeutics κατέβαλε μια μέρισμα ύψους . Αυτό αντιστοιχεί σε απόδοση μερίσματος περίπου . Για τους επόμενους 12 μήνες, η Odonate Therapeutics προβλέπεται να πληρώσει μέρισμα 0 USD.

Η απόδοση μερίσματος της Odonate Therapeutics ανέρχεται σήμερα στο .

Odonate Therapeutics πληρώνει τέταρτον διανεμητέου μισθό. Αυτή καταβάλλεται τους μήνες .

Η Odonate Therapeutics πλήρωσε κάθε χρόνο μέρισμα μέσα στα τελευταία 0 έτη.

Για τους επόμενους 12 μήνες αναμένονται μερίσματα σε ύψος των 0 USD. Αυτό αντιστοιχεί σε απόδοση μερίσματος 0 %.

Το Odonate Therapeutics ανατίθεται στον τομέα 'Υγεία'.

Για να λάβεις το τελευταίο μέρισμα των Odonate Therapeutics από την 5/11/2024 με τιμή 0 USD, έπρεπε να έχεις τη μετοχή στο χαρτοφυλάκιο σου πριν από την ημέρα Ex-Tag στις 5/11/2024.

Η τελευταία μερίσματος έγινε στις 5/11/2024.

Το έτος 2023, η Odonate Therapeutics διένειμε 0 USD ως μερίσματα.

Τα μερίσματα του Odonate Therapeutics καταβάλλονται σε USD.